Published in Curr Opin Genet Dev on December 29, 2013
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | NCT01832870
Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model. Cell Metab (2016) 1.44
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res (2014) 0.85
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res Treat (2015) 0.79
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
CD86 polymorphism affects pneumonia-induced sepsis by decreasing gene expression in monocytes. Inflammation (2015) 0.77
Metabolic Reprogramming in Glioma. Front Cell Dev Biol (2017) 0.77
Microfluidics: A new tool for modeling cancer-immune interactions. Trends Cancer (2016) 0.76
Human tissue models in cancer research: looking beyond the mouse. Dis Model Mech (2017) 0.75
Safety profile of EGFR-targeted hybrid vector system composed of PAMAM dendrimer and oncolytic adenovirus. J Thorac Dis (2017) 0.75
The FDA Guidance on Therapeutic Cancer Vaccines: The Need for Revision to Include Preventive Cancer Vaccines or for a New Guidance Dedicated to Them. Cancer Prev Res (Phila) (2015) 0.75
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy. J Immunother Cancer (2017) 0.75
TEMPORARY REMOVAL: Synthetic nanovaccines for immunotherapy. J Control Release (2017) 0.75
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood (2010) 2.19
Cytotoxic T cells. J Invest Dermatol (2006) 1.47
On immunosurveillance in human cancer. Yale J Biol Med (1983) 1.24
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 1.21
Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res (2009) 1.12
Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. J Natl Cancer Inst (1979) 1.07
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
Adoptive cellular therapy. Curr Top Microbiol Immunol (2011) 0.94
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92